Liver FibrosesNCT04155398
EUS Elastography for Predicting Cirrhotic-related Complications
An observational study of Liver Fibroses, run by Chinese University of Hong Kong at 1 site in Hong Kong.
Trial summary
Evaluation of the tissue stiffness as a surrogate marker of degree of liver cirrhosis has gained popularity in recent decades. Current guidelines also advocate the use of Fibroscan® machine (EchoSens, Paris, France) to detect any advanced liver fibrosis as represented by high liver stiffness, for prediction of varices… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Liver Fibroses
- What is being tested?
- EUS elastography
- Type of treatment
- Surgery or procedure
- How many people
- 50 participants
- Where
- 1 siteHong Kong
- Study dates
- 4 Nov 2019to 31 Dec 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: Patients with radiologic features suggestive of cirrhosis on abdominal imaging studies such as transabdominal ultrasound, CT or MRI and indication for variceal screening, suspected advanced liver fibrosis as detected by Fibroscan, or with clinical evidence of hypersplenism would be invited for the study
Who may be able to join
- Patients with radiologic features suggestive of cirrhosis on abdominal imaging studies such as transabdominal ultrasound, CT or MRI and indication for variceal screening
- Patients with suspected advanced liver fibrosis as detected by Fibroscan
- Patients with clinical evidence of hypersplenism
- Age > 18 years
- Written informed consent available
Who cannot join
- Patients with features of decompensated cirrhosis, such as history of ascites, prior variceal bleeding, hepatic encephalopathy, hepatorenal syndrome
- Patients with history of hepatocellular carcinoma
- Patients with history of liver transplant or TIPS or shunting surgery
- Patients with portal and/or mesenteric vein thrombosis
- Moribund patients from terminal illnesses
- Patients with terminal malignancy
Show all 9Show fewer
- Contraindications for endoscopy
- Unable to provide written informed consent
- Pregnancy
Trial locations and contacts
1 site in 1 country.
Hong Kong1 site
Prince of Wales Hospital, The Chinese University of Hong Kong
Shatin, New Territories
About this study
Official title: A Prospective Study on the Utility of Endoscopic Ultrasound Elastography (EUS-E) for Predicting Cirrhotic-related Complications in Patients With Chronic Liver Diseases
Evaluation of the tissue stiffness as a surrogate marker of degree of liver cirrhosis has gained popularity in recent decades. Current guidelines also advocate the use of Fibroscan® machine (EchoSens, Paris, France) to detect any advanced liver fibrosis as represented by high liver stiffness, for prediction of varices development.
Apart from liver stiffness, studies have shown that spleen stiffness (SS) has been proven another useful parameter to severity of underlying portal hypertension and liver cirrhosis. However, spleen stiffness measurement by Fibroscan® is highly limited by the thickness of subcutaneous soft tissue or abdominal wall tissue, especially in obese subjects. It carries certain technical difficulty as well due to its deep-seated anatomical position.
Recently, the technique of endoscopic ultrasound elastography (EUS-E) has been described. It can overcome the limitations of Fibroscan by making measurements of liver and spleen stiffness through the gastric wall, which has a shorter distance than the abdominal wall. It also allows concomitant upper GI tract luminal examination, incorporating both esophagogastroduodenoscopy and elastography measurements into one procedure at the same time. This research study aims to prospectively study the utility of EUS-E in patients with chronic liver diseases, both in terms of diagnostic and prognostic indications for future cirrhotic-related complications.
Read the detailed description
Portal hypertension is a severe consequence of chronic liver diseases and is responsible for multiple main clinical complications of liver cirrhosis. Gastroesophageal variceal bleeding is one of the notorious causes of cirrhosis-related morbidity and mortality, as a direct consequence of portal hypertension. Bleeding is usually major and carries 42% medical mortality at 6 weeks. 60% of early deaths and 40% of late deaths were attributable to bleeding. Approximately one-third of patients experienced rebleeding within 6 weeks and one-third of survivors experienced subsequent bleeds.
Assessment for portal hypertension is therefore of paramount importance. The gold standard of measurement of hepatic venous pressure gradient (HPVG) requires catheterization of the portal vein and is rarely performed in daily clinical practice due to its high invasiveness. Evaluation of the tissue stiffness as a surrogate marker of degree of liver cirrhosis has gained popularity in the recent decade. Transient elastography (TE) is one of the well proven tools to obtain liver stiffness measurements, which demonstrates good direct correlation to liver histology fibrosis staging. It also has satisfactory diagnostic performance for the prediction of clinically significant portal hypertension (HVPG > 10 mmHg) in the setting of compensated chronic liver disease or cirrhosis, with an area under receiver operating characteristics (AUROC) of 0.93. The Baveno VI criteria is one of the excellent examples to utilize TE liver stiffness measurements, all together with consideration of the platelet count, to screen out low risk patients for upper endoscopy variceal screening.
With reference to the basic anatomy, apart from liver stiffness, spleen stiffness (SS) becomes another potential quantitative parameter to the severity of underlying portal hypertension. A non-inferiority, open-label, randomized controlled trial across two hospitals in Hong Kong showed that high SS measurement by TE was independently associated with clinical significant varices. It was shown that a SSM cutoff value <41.3 kPa was sensitive and able to accurately rule out the presence of varices. Another study from Korea, with the use of acoustic radiation force impulse (ARFI) imaging, also demonstrated that SS was significantly higher in patients with varices than in those without varices (3.58 ± 0.47 vs 3.02 ± 0.49; P < 0.001). Increasing SS was observed in patients with higher grades of varices (No varix, 3.02 ± 0.49; F1, 3.39 ± 0.51; F2, 3.60 ± 0.42; F3, 3.85 ± 0.37; P < 0.001), as well as in patients who experienced variceal hemorrhage than in those who did not (3.80 ± 0.36 vs 3.20 ± 0.51; P = 0.002).
The most common way of TE is using the Fibroscan® machine (EchoSens, Paris, France). It is done by placement of a machine probe at right intercostal space over the liver parenchyma, which delivers a vibration and determines the liver stiffness by measuring the velocity of the vibration wave. It is able to measure a volume of approximately 10mm (wide) x 40mm (length) at a 25-65mm depth below the skin surface. However, it is highly limited by the thickness of subcutaneous soft tissue or abdominal wall tissue, especially in obese subjects. The spleen stiffness measurements carry certain technical difficulty as well due to its deep-seated anatomical position, particularly when it is not enlarged.
EUS elastography (EUS-E) makes use of another concept of direct tissue stiffness measurement, namely the real-time tissue elastography (RTE). It gauges the oscillation of tissue from adjacent vascular pulsation and compression, with the degree of deformation and displacement as an indicator of tissue stiffness. The tissue elasticity distribution is then represented in color superimposed on the conventional B mode image displayed. It can also be quantified in terms of Strain Ratio (SR) and Strain Histogram (SH) by machine calculation. Initially developed to differentiate benign soft tissue from malignant tumour, RTE has been used to characterize liver fibrosis in chronic liver disease of different aetiologies, as the liver is just adjacent to the stomach, which is a common scanningfield in EUS.
With such, EUS-E may offer a better option for liver and spleen stiffness measurements with the following advantages:
- EUS is expected to have a higher success rate for LS and SS measurements, with closer distance through the gastric wall to the parenchyma. This can overcome the limitations of TE in patients with extreme body habitus, thick abdominal wall muscles and also normal spleen size.
- Forward viewing radial echoendoscope and forward oblique viewing linear echoendoscope allow concomitant upper GI tract luminal examination, incorporating both oesophagogastroduodenoscopy (OGD) and elastography measurements into one procedure at the same time.
- EUS can apply Doppler signals to allow detection of "deep" submucosal varices, paraesophageal and para-gastric varices that may not be routinely observed during conventional endoscopy at luminal view.
Literature search reveals utilization of other means of TE measurements, such as ARFI and 2-D shear wave elastography in SS measurements to predict clinical outcomes, such as variceal bleeding. However, there are still no relevant studies on EUS-E in terms of liver and stiffness measurements with correlation to development of cirrhotic complications, despite its more popular use and availability. Thus, investigators aim to prospectively study the utility of EUS-E in patients with chronic liver diseases, both in terms of diagnostic and prognostic indications for future cirrhotic-related complications.
- Conditions
- Liver Fibroses
- Being tested
- EUS elastography
- Keywords
- liver stiffness, EUS elastography
- Medical subject headings
- Liver Cirrhosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
EUS elastographyProcedure or surgery
A forward view radial echoendoscope or a forward oblique view linear echoendoscope would be used to perform focused luminal examination of varices and EUS elastography for measurement of liver stiffness and spleen stiffness.
| Study group | Role | What they receive |
|---|---|---|
| Study group | Patients with radiologic features suggestive of cirrhosis on abdominal imaging studies such as transabdominal ultrasound, CT or MRI and indication for variceal screening, suspected advanced liver fibrosis as detected by Fibroscan, or with clinical evidence of hypersplenism would be invited for the study Receives: Procedure: EUS elastography |
What is being measured
The primary outcome is the main question the study is designed to answer.
Inter-observer and intra-observer variability of liver and spleen stiffness measurements by EUS-E among endoscopists with different EUS experience
Inter-observer and intra-observer variability of liver and spleen stiffness measurements by EUS-E among endoscopists with different EUS experience
Measured: peri-procedure
Diagnostic performance of liver and spleen stiffness measurements by EUS-E to predict variceal development and/or bleeding
Diagnostic performance of liver and spleen stiffness measurements by EUS-E to predict variceal development and/or bleeding
Measured: Follow up for 2 years after index study endoscopy
Secondary outcomes (3)
Diagnostic performance of liver and spleen stiffness measurements by EUS-E to predict other liver cirrhosis complications (eg, ascites, hepatic encelopathy, etc)
Diagnostic performance of liver and spleen stiffness measurements by EUS-E to predict other liver cirrhosis complications (eg, ascites, hepatic encelopathy, etc)
Measured: Follow up for 2 years after index study endoscopy
Correlation of liver fibrosis by EUS-E to Fibroscan
Correlation of liver fibrosis by EUS-E to Fibroscan
Measured: Follow up for 2 years after index study endoscopy
Adverse events related to procedure
Adverse events related to procedure
Measured: peri-procedure
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Nov 2019
- Study start4 Nov 2019
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Liver FibrosesStudies of the same condition, open and under way.
- More trials run by Chinese University of Hong KongThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Chinese University of Hong Kong
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Raymond Shing Yan Tang, Chinese University of Hong Kong
- Investigators
- Raymond Tang, MD, Principal investigator, Chinese University of Hong Kong
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04155398
- Sponsor's protocol ID
- EUS-E study
- Status last verified
- Mar 2026
- First submitted
- 3 Nov 2019
- Last updated
- 19 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective Study on the Utility of Endoscopic Ultrasound Elastography (EUS-E) for Predicting Cirrhotic-related Complications in Patients With Chronic Liver Diseases
- ClinicalTrials.gov ID
- NCT04155398
- Acronym / sponsor ID
- EUS-E study
- Conditions
- Liver Fibroses
- Keywords
- liver stiffness, EUS elastography
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Chinese University of Hong KongUniversity, hospital or other
- Study start
- 4 Nov 2019 (actual)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 7 Nov 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Evaluation of the tissue stiffness as a surrogate marker of degree of liver cirrhosis has gained popularity in recent decades. Current guidelines also advocate the use of Fibroscan® machine (EchoSens, Paris, France) to detect any advanced liver fibrosis as represented by high liver stiffness, for prediction of varices development.
Apart from liver stiffness, studies have shown that spleen stiffness (SS) has been proven another useful parameter to severity of underlying portal hypertension and liver cirrhosis. However, spleen stiffness measurement by Fibroscan® is highly limited by the thickness of subcutaneous soft tissue or abdominal wall tissue, especially in obese subjects. It carries certain technical difficulty as well due to its deep-seated anatomical position.
Recently, the technique of endoscopic ultrasound elastography (EUS-E) has been described. It can overcome the limitations of Fibroscan by making measurements of liver and spleen stiffness through the gastric wall, which has a shorter distance than the abdominal wall. It also allows concomitant upper GI tract luminal examination, incorporating both esophagogastroduodenoscopy and elastography measurements into one procedure at the same time. This research study aims to prospectively study the utility of EUS-E in patients with chronic liver diseases, both in terms of diagnostic and prognostic indications for future cirrhotic-related complications.
Detailed description
Portal hypertension is a severe consequence of chronic liver diseases and is responsible for multiple main clinical complications of liver cirrhosis. Gastroesophageal variceal bleeding is one of the notorious causes of cirrhosis-related morbidity and mortality, as a direct consequence of portal hypertension. Bleeding is usually major and carries 42% medical mortality at 6 weeks. 60% of early deaths and 40% of late deaths were attributable to bleeding. Approximately one-third of patients experienced rebleeding within 6 weeks and one-third of survivors experienced subsequent bleeds.
Assessment for portal hypertension is therefore of paramount importance. The gold standard of measurement of hepatic venous pressure gradient (HPVG) requires catheterization of the portal vein and is rarely performed in daily clinical practice due to its high invasiveness. Evaluation of the tissue stiffness as a surrogate marker of degree of liver cirrhosis has gained popularity in the recent decade. Transient elastography (TE) is one of the well proven tools to obtain liver stiffness measurements, which demonstrates good direct correlation to liver histology fibrosis staging. It also has satisfactory diagnostic performance for the prediction of clinically significant portal hypertension (HVPG > 10 mmHg) in the setting of compensated chronic liver disease or cirrhosis, with an area under receiver operating characteristics (AUROC) of 0.93. The Baveno VI criteria is one of the excellent examples to utilize TE liver stiffness measurements, all together with consideration of the platelet count, to screen out low risk patients for upper endoscopy variceal screening.
With reference to the basic anatomy, apart from liver stiffness, spleen stiffness (SS) becomes another potential quantitative parameter to the severity of underlying portal hypertension. A non-inferiority, open-label, randomized controlled trial across two hospitals in Hong Kong showed that high SS measurement by TE was independently associated with clinical significant varices. It was shown that a SSM cutoff value <41.3 kPa was sensitive and able to accurately rule out the presence of varices. Another study from Korea, with the use of acoustic radiation force impulse (ARFI) imaging, also demonstrated that SS was significantly higher in patients with varices than in those without varices (3.58 ± 0.47 vs 3.02 ± 0.49; P < 0.001). Increasing SS was observed in patients with higher grades of varices (No varix, 3.02 ± 0.49; F1, 3.39 ± 0.51; F2, 3.60 ± 0.42; F3, 3.85 ± 0.37; P < 0.001), as well as in patients who experienced variceal hemorrhage than in those who did not (3.80 ± 0.36 vs 3.20 ± 0.51; P = 0.002).
The most common way of TE is using the Fibroscan® machine (EchoSens, Paris, France). It is done by placement of a machine probe at right intercostal space over the liver parenchyma, which delivers a vibration and determines the liver stiffness by measuring the velocity of the vibration wave. It is able to measure a volume of approximately 10mm (wide) x 40mm (length) at a 25-65mm depth below the skin surface. However, it is highly limited by the thickness of subcutaneous soft tissue or abdominal wall tissue, especially in obese subjects. The spleen stiffness measurements carry certain technical difficulty as well due to its deep-seated anatomical position, particularly when it is not enlarged.
EUS elastography (EUS-E) makes use of another concept of direct tissue stiffness measurement, namely the real-time tissue elastography (RTE). It gauges the oscillation of tissue from adjacent vascular pulsation and compression, with the degree of deformation and displacement as an indicator of tissue stiffness. The tissue elasticity distribution is then represented in color superimposed on the conventional B mode image displayed. It can also be quantified in terms of Strain Ratio (SR) and Strain Histogram (SH) by machine calculation. Initially developed to differentiate benign soft tissue from malignant tumour, RTE has been used to characterize liver fibrosis in chronic liver disease of different aetiologies, as the liver is just adjacent to the stomach, which is a common scanningfield in EUS.
With such, EUS-E may offer a better option for liver and spleen stiffness measurements with the following advantages:
- EUS is expected to have a higher success rate for LS and SS measurements, with closer distance through the gastric wall to the parenchyma. This can overcome the limitations of TE in patients with extreme body habitus, thick abdominal wall muscles and also normal spleen size.
- Forward viewing radial echoendoscope and forward oblique viewing linear echoendoscope allow concomitant upper GI tract luminal examination, incorporating both oesophagogastroduodenoscopy (OGD) and elastography measurements into one procedure at the same time.
- EUS can apply Doppler signals to allow detection of "deep" submucosal varices, paraesophageal and para-gastric varices that may not be routinely observed during conventional endoscopy at luminal view.
Literature search reveals utilization of other means of TE measurements, such as ARFI and 2-D shear wave elastography in SS measurements to predict clinical outcomes, such as variceal bleeding. However, there are still no relevant studies on EUS-E in terms of liver and stiffness measurements with correlation to development of cirrhotic complications, despite its more popular use and availability. Thus, investigators aim to prospectively study the utility of EUS-E in patients with chronic liver diseases, both in terms of diagnostic and prognostic indications for future cirrhotic-related complications.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Study group | – | Procedure: EUS elastographyPatients with radiologic features suggestive of cirrhosis on abdominal imaging studies such as transabdominal ultrasound, CT or MRI and indication for variceal screening, suspected advanced liver fibrosis as detected by Fibroscan, or with clinical evidence of hypersplenism would be invited for the study |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- Patients with radiologic features suggestive of cirrhosis on abdominal imaging studies such as transabdominal ultrasound, CT or MRI and indication for variceal screening, suspected advanced liver fibrosis as detected by Fibroscan, or with clinical evidence of hypersplenism would be invited for the study
Key inclusion criteria (5 listed)
- Patients with radiologic features suggestive of cirrhosis on abdominal imaging studies such as transabdominal ultrasound, CT or MRI and indication for variceal screening
- Patients with suspected advanced liver fibrosis as detected by Fibroscan
- Patients with clinical evidence of hypersplenism
- Age > 18 years
- Written informed consent available
Key exclusion criteria (9 listed)
- Patients with features of decompensated cirrhosis, such as history of ascites, prior variceal bleeding, hepatic encephalopathy, hepatorenal syndrome
- Patients with history of hepatocellular carcinoma
- Patients with history of liver transplant or TIPS or shunting surgery
- Patients with portal and/or mesenteric vein thrombosis
- Moribund patients from terminal illnesses
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| EUS elastographyA forward view radial echoendoscope or a forward oblique view linear echoendoscope would be used to perform focused luminal examination of varices and EUS elastography for measurement of liver stiffness and spleen stiffness. | Procedure or surgery | Study group |
Primary outcome
Inter-observer and intra-observer variability of liver and spleen stiffness measurements by EUS-E among endoscopists with different EUS experience
Time frame: peri-procedure
Inter-observer and intra-observer variability of liver and spleen stiffness measurements by EUS-E among endoscopists with different EUS experience
Diagnostic performance of liver and spleen stiffness measurements by EUS-E to predict variceal development and/or bleeding
Time frame: Follow up for 2 years after index study endoscopy
Diagnostic performance of liver and spleen stiffness measurements by EUS-E to predict variceal development and/or bleeding
3 secondary outcomes
Diagnostic performance of liver and spleen stiffness measurements by EUS-E to predict other liver cirrhosis complications (eg, ascites, hepatic encelopathy, etc)
Time frame: Follow up for 2 years after index study endoscopy
Correlation of liver fibrosis by EUS-E to Fibroscan
Time frame: Follow up for 2 years after index study endoscopy
Adverse events related to procedure
Time frame: peri-procedure
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Mar 2026.
- Individual participant dataSharing planned: No
Related trials for Liver Fibroses
Enrolling by invitationPhase 2/3
A Multicenter, Randomized, Controlled Trial of Prednisone Combined With Ursodeoxycholic Acid in the Treatment of Primary Biliary Cholangitis With Moderate to Severe Interface Hepatitis Characteristics
Primary Biliary Cholangitis (PBC)
Not yet recruiting
Prickly Pear Pulp Powder Along With an Anti-inflammatory Diet in Patients Having Liver Fibrosis
Lipid Profile, Blood Glucose
Active, not recruitingObservational study
Assessment of the Prevalence of Steatotic Liver Disease Associated With Metabolic Dysfunction in Patients With Heterozygous Familial Hypercholesterolemia
Heterozygous Familial Hypercholesterolemia
RecruitingObservational study
Natural History of Noncirrhotic Portal Hypertension
Cystic Fibrosis, Immunologic Deficiency Syndrome
Active, not recruitingPhase 2/3
Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis
Primary Biliary Cholangitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Raymond Tang, MD principal investigator
Chinese University of Hong Kong
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Liver Fibroses, run by Chinese University of Hong Kong at 1 site in Hong Kong.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 19 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Hong Kong. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Inter-observer and intra-observer variability of liver and spleen stiffness measurements by EUS-E among endoscopists with different EUS experience (time frame: peri-procedure). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Mar 2026.